Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood samples may unlock secrets of a common epilepsy

NCT ID NCT03400371

Knowledge-focused Sponsor: King's College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aims to find the genetic causes of juvenile myoclonic epilepsy (JME) by collecting blood samples from over 1,000 people with JME across the UK, Europe, and North America. Researchers will compare their DNA to samples from 2,000 healthy controls. The goal is to improve treatments and enable earlier detection of the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward better treatments and earlier detection for juvenile myoclonic epilepsy.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and genetic findings can take years to translate into clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People in the UK, Europe, and North America with a diagnosis of Juvenile Myoclonic Epilepsy.

Ages

10 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria * Age of myoclonus onset 10-25 years * Seizures comprising predominant or exclusive early morning myoclonus of upper extremities * EEG interictal generalized spikes and/or polyspike and waves with normal background * Current age 10-40 years Exclusion Criteria: * Myoclonus only associated with carbamazepine or lamotrigine therapy * EEG showing predominant focal interictal epileptiform discharges or abnormal background * Any evidence of progressive or symptomatic myoclonus epilepsy or focal seizures * Global learning disability * Dysmorphic syndrome * Unable to provide informed consent Regrettably, we are currently unable to accept self-referrals to the BIOJUME study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myoclonic epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy juvenile myoclonic epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myoclonic epilepsy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charles University

    RECRUITING

    Prague, 116 36, Czechia

  • Commissione Genetica Lega Italiana contro l'Epilepssia

    RECRUITING

    Roma, 00198, Italy

  • Danish National Epilepsy Centre

    RECRUITING

    Dianalund, 4293, Denmark

  • Hospital for Sick Kids

    RECRUITING

    Toronto, Ontario, M5G 0A4, Canada

  • King's College Hospital NHS Trust

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Mount Sinai-Beth Israel Medical Center

    COMPLETED

    New York, New York, 10003, United States

  • Nationwide Children's Hospital

    COMPLETED

    Columbus, Ohio, 43125, United States

  • Royal London Hospital

    RECRUITING

    London, E1 1BZ, United Kingdom

  • St Luke's Roosevelt Hospital

    COMPLETED

    New York, New York, 10025, United States

  • St Thomas' Hospital

    RECRUITING

    London, SE1 9HT, United Kingdom

  • Swansea University

    RECRUITING

    Swansea, SA2 8PP, United Kingdom

  • Tallinn Children's Hospital

    RECRUITING

    Tallinn, 13419, Estonia

  • University Robert Debré

    RECRUITING

    Paris, 75019, France

  • Vestre Viken Health Trust, Oslo

    RECRUITING

    Drammen, 3004, Norway

  • Walton Centre for Neurology and Neurosurgery

    RECRUITING

    Liverpool, L9 7LJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.